Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
deoxythymidine monophosphate is a nucleotide, specifically the monophosphate ester of the nucleoside thymidine, which itself consists of the nucleobase thymine attached to deoxyribose. Its structure comprises a phosphate group, deoxyribose sugar, and thymine base[1][3][7]. It is one of the four deoxyribonucleotides required for the synthesis of DNA and is a critical fundamental metabolite in cellular processes. Therapeutically, deoxythymidine monophosphate has been investigated as a supplement for genetic mitochondrial diseases caused by thymidine kinase 2 (TK2) deficiency, where it acts by bypassing defective nucleotide salvage pathways, restoring mitochondrial DNA levels, and improving biochemical and phenotypic outcomes in preclinical models[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on deoxythymidine monophosphate.